132 related articles for article (PubMed ID: 21983440)
1. One-class classification as a novel method of ligand-based virtual screening: the case of glycogen synthase kinase 3β inhibitors.
Karpov PV; Osolodkin DI; Baskin II; Palyulin VA; Zefirov NS
Bioorg Med Chem Lett; 2011 Nov; 21(22):6728-31. PubMed ID: 21983440
[TBL] [Abstract][Full Text] [Related]
2. Identification and in vitro evaluation of new leads as selective and competitive glycogen synthase kinase-3β inhibitors through ligand and structure based drug design.
Darshit BS; Balaji B; Rani P; Ramanathan M
J Mol Graph Model; 2014 Sep; 53():31-47. PubMed ID: 25064440
[TBL] [Abstract][Full Text] [Related]
3. Structure-based virtual screening of glycogen synthase kinase 3β inhibitors: analysis of scoring functions applied to large true actives and decoy sets.
Osolodkin DI; Palyulin VA; Zefirov NS
Chem Biol Drug Des; 2011 Sep; 78(3):378-90. PubMed ID: 21679374
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and structure-activity relationships of 1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3beta.
Saitoh M; Kunitomo J; Kimura E; Hayase Y; Kobayashi H; Uchiyama N; Kawamoto T; Tanaka T; Mol CD; Dougan DR; Textor GS; Snell GP; Itoh F
Bioorg Med Chem; 2009 Mar; 17(5):2017-29. PubMed ID: 19200745
[TBL] [Abstract][Full Text] [Related]
5. Comparative virtual and experimental high-throughput screening for glycogen synthase kinase-3beta inhibitors.
Polgár T; Baki A; Szendrei GI; Keseru GM
J Med Chem; 2005 Dec; 48(25):7946-59. PubMed ID: 16335919
[TBL] [Abstract][Full Text] [Related]
6. 3D-QSAR and docking studies of selective GSK-3beta inhibitors. Comparison with a thieno[2,3-b]pyrrolizinone derivative, a new potential lead for GSK-3beta ligands.
Lescot E; Bureau R; Sopkova-de Oliveira Santos J; Rochais C; Lisowski V; Lancelot JC; Rault S
J Chem Inf Model; 2005; 45(3):708-15. PubMed ID: 15921460
[TBL] [Abstract][Full Text] [Related]
7. In-Silico Screening of Ligand Based Pharmacophore, Database Mining and Molecular Docking on 2, 5-Diaminopyrimidines Azapurines as Potential Inhibitors of Glycogen Synthase Kinase-3β.
Mishra P; Kesar S; Paliwal SK; Chauhan M; Madan K
Cent Nerv Syst Agents Med Chem; 2018; 18(2):150-158. PubMed ID: 29848281
[TBL] [Abstract][Full Text] [Related]
8. Novel GSK-3beta inhibitors from sequential virtual screening.
Kim HJ; Choo H; Cho YS; No KT; Pae AN
Bioorg Med Chem; 2008 Jan; 16(2):636-43. PubMed ID: 18006321
[TBL] [Abstract][Full Text] [Related]
9. Pharmacophore modeling, quantitative structure-activity relationship analysis, and in silico screening reveal potent glycogen synthase kinase-3beta inhibitory activities for cimetidine, hydroxychloroquine, and gemifloxacin.
Taha MO; Bustanji Y; Al-Ghussein MA; Mohammad M; Zalloum H; Al-Masri IM; Atallah N
J Med Chem; 2008 Apr; 51(7):2062-77. PubMed ID: 18324764
[TBL] [Abstract][Full Text] [Related]
10. 3D-QSAR and molecular docking studies on 3-anilino-4-arylmaleimide derivatives as glycogen synthase kinase-3β inhibitors.
Akhtar M; Bharatam PV
Chem Biol Drug Des; 2012 Apr; 79(4):560-71. PubMed ID: 22168279
[TBL] [Abstract][Full Text] [Related]
11. Structure-Based Discovery of 1H-Indazole-3-carboxamides as a Novel Structural Class of Human GSK-3 Inhibitors.
Ombrato R; Cazzolla N; Mancini F; Mangano G
J Chem Inf Model; 2015 Dec; 55(12):2540-51. PubMed ID: 26600430
[TBL] [Abstract][Full Text] [Related]
12. Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3β inhibitors through virtual screening.
Zhang P; Hu HR; Huang ZH; Lei JY; Chu Y; Ye DY
Bioorg Med Chem Lett; 2012 Dec; 22(23):7232-6. PubMed ID: 23099099
[TBL] [Abstract][Full Text] [Related]
13. Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models.
Vadivelan S; Sinha BN; Tajne S; Jagarlapudi SA
Eur J Med Chem; 2009 Jun; 44(6):2361-71. PubMed ID: 18929433
[TBL] [Abstract][Full Text] [Related]
14. A new protocol for predicting novel GSK-3β ATP competitive inhibitors.
Fang J; Huang D; Zhao W; Ge H; Luo HB; Xu J
J Chem Inf Model; 2011 Jun; 51(6):1431-8. PubMed ID: 21615159
[TBL] [Abstract][Full Text] [Related]
15. Investigation of potential glycogen synthase kinase 3 inhibitors using pharmacophore mapping and virtual screening.
Dessalew N; Bharatam PV
Chem Biol Drug Des; 2006 Sep; 68(3):154-65. PubMed ID: 17062013
[TBL] [Abstract][Full Text] [Related]
16. 3D-QSAR and molecular docking studies on pyrazolopyrimidine derivatives as glycogen synthase kinase-3beta inhibitors.
Dessalew N; Patel DS; Bharatam PV
J Mol Graph Model; 2007 Mar; 25(6):885-95. PubMed ID: 17018257
[TBL] [Abstract][Full Text] [Related]
17. Design of glycogen synthase kinase-3 inhibitors: an overview on recent advancements.
Arfeen M; Bharatam PV
Curr Pharm Des; 2013; 19(26):4755-75. PubMed ID: 23260024
[TBL] [Abstract][Full Text] [Related]
18. Identification of small molecules that inhibit GSK-3beta through virtual screening.
Kang NS; Lee GN; Kim CH; Bae MA; Kim I; Cho YS
Bioorg Med Chem Lett; 2009 Jan; 19(2):533-7. PubMed ID: 19081248
[TBL] [Abstract][Full Text] [Related]
19. Receptor-based pharmacophore modeling, virtual screening, and molecular docking studies for the discovery of novel GSK-3β inhibitors.
El Kerdawy AM; Osman AA; Zaater MA
J Mol Model; 2019 May; 25(6):171. PubMed ID: 31129879
[TBL] [Abstract][Full Text] [Related]
20. E-pharmacophore-based virtual screening to identify GSK-3β inhibitors.
Natarajan P; Priyadarshini V; Pradhan D; Manne M; Swargam S; Kanipakam H; Bhuma V; Amineni U
J Recept Signal Transduct Res; 2016 Oct; 36(5):445-58. PubMed ID: 27305963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
